Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 15;129(2):181-183.
doi: 10.1002/cncr.34558. Epub 2022 Nov 24.

Immunotherapy partners after progression: Right place, right time?

Sherin J Rouhani  1   2 , Christine M Bestvina  1   2
Affiliations
Free article
Editorial

Immunotherapy partners after progression: Right place, right time?

Sherin J Rouhani et al. Cancer. .
Free article
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer, Version 4. 2022. Accessed September 9, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
    1. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597. doi:10.1200/JCO.2004.08.163
    1. Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673. doi:10.1016/S0140-6736(14)60845-X
    1. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103. doi:10.1200/JCO.2000.18.10.2095
    1. Salous T, Shukla NA, Althouse SK, et al. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029. Cancer. 2022;129(2):264-271. doi:10.1002/cncr.34558

LinkOut - more resources